Get started

Healthcare

Healthcare Critical LevelTechnical Analysis The 200ema has been tested several times, and has worked very well as a mid-term support level. Risk reward ratio is easy to set-up with a 3:1 ratio approximately. Sector & Industry Analysis It is important to note that the industries inside the sector have different performance, which has been very useful to analyze what the market thinks of the risk of healthcare with the election coming up. The following list is the Healthcare Industries with a 6-month performance % move, as well as a some good ETF to follow/trade: Healthcare Technology --> +56% // have not found appropriate ETF. Biotechnology --> +21% // XBI (smaller biotech), IBB (large-cap biotech), ARKG (genomics) Healthcare Equipment --> +19% // IHI Healthcare Providers --> +5.51% // IHF Pharmaceuticals --> -1.3% // IHE
AMEX:XLV
by dorfmanmaster
Unheard gross margins of 95% and a $800B TAM : $GDRXGoodRx is a free-to-use service that allows Americans to find the lowest-cost prescription drugs in their area. The company makes money by receiving a commission for every prescription order filled via its coupons, which are accepted by nearly all 70,000 pharmacies across the country. -Most Downloaded medical app in US with 4.8/5 rating(700,000+ reviews) -Partnership with Kroger -Competing with TDOC with the launch of HeyDoctor - Rising prices of pharmaceuticals and their mission is to lower the cost of healthcare -95% Gross margin (What?!?!). 30% Operating margin. - $75M Free cash flow. - TAM $800 Mn - NPS 86 - 4.6/5 Glassdoor - Founder led Concerns, 1. P/S of 37.1 and 201 PE. Average PE in healthcare is 24. 2. IPO hype(good for trades though) 3. 94% of top line revenue still coming in from prescription stream(concentration risk?) which grew 42% Q1. 4. Regulations 5. International expansion? 6. 4 holders own 60-65% of the company(Both good and bad) TA, 1. Wedge breakout 2. Potential base of Cup. 3. Low volume on Pullback Not a long term position yet. Swing trade. Entry : break of 52 Stop loss : 49 (-7.8%)
NASDAQ:GDRXLong
by ashainp
2
SPHealth 2 Week Comparisons (Oct 7-20 2020)SPHealth - Growth Analysis & Comparison - Cindicator Poll Submission (October 7th - 20th 2020) I've been looking through my Cindicator questions, making forecasts and watching markets as new polls pop up. Here's a comparison chart for 5 major S&P health companies and my rankings forecast. (Descending order from most growth to least) United Health Group Inc (UNH) Abbott Labs (ABT) Johnson & Johnson (JNJ) Pfizer Inc. (PFE) Merck & Co. (MRK) This forecast will be explicitly graded by total growth % comparisons of opening prices on October 7th to closing prices on October 20th across the 5 aforementioned companies. As of right now before 10-9-20 daily market open, the percentage growth is as follows: UNH +1.9% PFE +1.87% JNJ +1.56% ABT +1.1% MRK +0.54% When looking at a specific metric within the already completed duration since I submitted my forecast, overall recent growth is: UNH +2.82% PFE +2.66% JNJ +2.24% MRK +2.22% ABT +1.62% 10-9-20 Forecast Adjustments: Now that I have seen the last 2 days play out, I'm starting to notice a couple things about my forecast and actual live value. I'm confident that United Health will still outperform, but this outlook could change if any major market sell off occurs before the 20th. Pfizer looks like it could be a strong runner up, and I may have flubbed my original forecast by ranking it 4th in growth. Johnson & Johnson is performing approximately as expected. Merck and Abbott Labs could be tricky to pinpoint exactly without some further research and analysis but, I'm guessing that Abbott may come in 4th place if everything settles after any quick rallies that should happen. If a light pump in Merck occurs over the 19th-20th, then there could be a small chance it outperforms Abbott for 4th but it feels like an unlikely scenario. After these deliberations, I've decided my forecast doesn't need much adjusting other than to swap the placement of Pfizer and Abbott. My updated forecast is as follows: United Health Group Inc (UNH) Pfizer Inc. (PFE) Johnson & Johnson (JNJ) Abbott Labs (ABT) Merck & Co. (MRK) One thing to note is that I believe TradingView is not calculating its percentage scale correctly, its placing the 0% Y axis at the close value of the first candle used to calculate growth. So this graph is really just more for me to check my own work by hand, as the percentages on the left will not accurately portray what is actually being graded by Cindicator. I'll check back in after the 20th to see how this turned out! Thanks for tuning in :) Disclaimer, I am not responsible for any losses incurred while attempting to use my data, I hope this can prove to be some sort of learning tool for some and give insight as to how I personally come up with my own numbers. Take into full consideration this could be a completely bad forecast. Cheers
NYSE:UNH
by Hambooger
$LMAT can rise in the next daysContextual immersion trading strategy idea. LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The demand for shares of the company looks higher than the supply. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $33,45; stop-loss — $32,46. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:LMATLong
by KozakHlib
$AVDL can fall in the next daysContextual immersion trading strategy idea. Avadel Pharmaceuticals operates as a specialty pharmaceutical company in the United States, France, and Ireland. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price in the next days. So I opened a short position from $5,23; stop-loss — $5,89. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:AVDLShort
by KozakHlib
$CODX can rise in the next daysContextual immersion trading strategy idea. Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. The share price rose after the company announced that it had entered into an agreement with Arches Research, a subsidiary of Polarity TE (NASDAQ:PTE), to expand Arches' use of Co-Diagnostics' Logix Smart COVID-19 test. The demand for shares of the company still looks higher than the supply. These and other conditions can cause a rise in the share price in the next days. So I opened a long position again from $11,62; stop-loss — $10,80. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:CODXLong
by KozakHlib
$MASI can fall in the next daysContextual immersion trading strategy idea. Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price in the next days. So I opened a short position from $218,41; stop-loss — $221,56. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:MASIShort
by KozakHlib
2
Possible Head & Shoulders for APHA?A H&S pattern is clearly noticeable on the RSI & KST. On the KST the right shoulder is lower than the left, but on the price the right shoulder is higher than the left, not sure if that's considered a bearish divergence but if there's further downside action it would seem accurate. On the KST each shoulder & the head display a bearish cross where I have placed the red finger, this happens when the red line crosses over the green in a downward angle.
A
by ScotianBot
1
Buying opportunity in CVS after Walgreens earnings bombCVS is pulling back in sympathy with Walgreens after WBA earnings were a dud. However, the adverse impact on Walgreens sales was "almost entirely from the company's non-U.S. businesses," according to the company's report. CVS operates almost exclusively in the United States, with 9,750 US locations and just 150 internationally. This suggests that CVS should be relatively insulated from the fall-off in international demand that Walgreens saw. CVS is in almost every way a better company than Walgreens. It has better analyst ratings, better financial health, and a much better valuation in terms of PEG ratio. Its dividend yield and dividend growth are lower, but its growth plan has been more aggressive, with the rollout of HealthHub stores and telehealth services continuing on schedule amidst the pandemic. Walgreens has lagged behind CVS in its plans to add healthcare clinics to its retail stores. CVS's relationship with UPS may prove an additional tailwind amidst the pandemic. Walgreens partners with UPS's smaller competitor, FedEx.
NYSE:CVSLong
by ChristopherCarrollSmith